This prospective longitudinal study examined both shortand long-term changes in health-related quality of life (HRQL) in 52 breast cancer patients with poor prognosis receiving high-dose chemotherapy (HDC) treatment with autologous blood stem cell transplantation (ASCT). HRQL was measured seven times from baseline to 2 years post enrollment with the Functional Living IndexCancer (FLIC), the EuroQol (EQ-5D), and a quality of life visual analogue scale. The percentage of questionnaires returned at each assessment time ranged from 80 to 92%. All three measures showed a similar pattern of change, with HRQL decreasing following administration of HDC, and returning to baseline levels 8 weeks post HDC. A repeated-measures analysis of variance showed that the FLIC at 2 years was significantly better than baseline (P ¼ o0.0001). Difficulty sleeping, headaches, and decreased sexual interest were the most common symptoms reported in the longer term. Our results have implications for early psychosocial intervention in the care of breast cancer patients with poor prognosis undergoing treatment with HDC and ASCT because such interventions can further improve the quality of their survival.
high-dose chemotherapy; stem cell transplantation; EQ-5D Breast cancer and its treatments can have a devastating effect on psychological and psychosexual functioning, with quality of life being compromised. Women whose breast cancer diagnosis has traditionally carried a poor prognosis are now surviving much longer following treatment. Health-related quality of life (HRQL) has therefore become an important outcome measure in breast cancer patients who have reported substantial, long-term treatment side effects such as fatigue, [1] [2] [3] sexual difficulties, 4, 5 and insomnia. 1, 4 There is little information about the long-term effects of high-dose chemotherapy (HDC) or autologous blood stem cell transplantation (ASCT) on HRQL in breast cancer patients. Most studies have been cross-sectional 6, 7 and, in the few longitudinal studies that have followed patients over the course of treatment, HRQL has been reported up to 1 year following treatment. 4, 8 There is an array of cancer-specific HRQL tools available that assess the effect of cancer on the physical, psychological, social functioning and wellbeing of individuals. In addition to cancer-specific tools, which focus on specific problems that are related to the disease, preferencebased generic tools are often used to assess the impact of health-care interventions on HRQL and are increasingly used in economic evaluations alongside cancer-specific tools to provide a more global measure of patient benefit. 9, 10 These tools are based on multidimensional health state classification systems, each with a set of preference weights. They generate a single index score that can be used as a measure of preference-based HRQL or can be combined with lifeyears for use in economic analysis.
This 2-year longitudinal study examined HRQL in breast cancer patients with poor prognosis (Stage II/III) receiving HDC with ASCT in a prospective Phase II clinical trial. A paper is in press documenting the results of the clinical trial. 11 The purpose of this Phase II trial was to evaluate the feasibility and outcome of treating breast cancer patients with poor prognosis with a high-dose regime consisting of mitoxantrone, vinblastine, and cyclophosphomide (MVC) with ASCT support. Our main objective in the currently reported companion study was to assess changes in HRQL and symptoms over the course of treatment and follow-up.
Patients and methods

Patients
The sample used in the HRQL study consisted of consecutive patients recruited at the Tom Baker Cancer Centre in Calgary from April 1995 to October 1998 with stage II and III breast cancer at high risk of relapse.
Eligibility criteria for patients who had undergone definitive surgical resection (post-operative group) included seven or more involved axillary nodes for patients with tumors less than 5 cm in size, or four or more involved axillary nodes for patients with T3 (45 cm) or T4 (involvement of skin or chest wall or inflammatory) tumors. Patients who received protocol chemotherapy pre-operatively were required to have T3 tumors and palpable axillary nodes, or T4 tumors regardless of axillary status. Other eligibility criteria included age 18-65 years and no definitive evidence of metastatic disease on chest radiographs, bone scan, or liver ultrasound. Patients who had abnormalities on these tests that were not strongly suggestive of metastases were considered eligible. Patients did require a WBC 43.0 Â 10 9 /l, platelet count 4100 Â 10 9 /l, creatinine o133 mmol/l, ALT o3 Â normal, bilirubin o3 Â normal, a left ventricular ejection fraction (LVEF) on MUGA nuclear cardiac scan over 0.50, and pulmonary function tests showing a forced vital capacity (FVC) 450% predicted, forced expiratory volume (FEV1) 450% predicted, and DLCO 450% predicted. The ECOG status was 0-2. All patients were required to give written informed consent prior to starting protocol therapy. The study received local approval from the University of Calgary scientific and research ethics board.
At the time of the clinical trial, stage II breast cancer included T1-2N1M0 (tumors o5 cm with involved but mobile axillary nodes) and stage III included T3-4N1-2M0 (T3-4: tumors 45 cm or adherent to skin or chest wall, or inflammatory breast cancer. N1-2: involved axillary nodes, mobile or fixed). Of note, the staging system for breast cancer has recently changed. Currently, with the change of staging system, stage II breast cancer is T1-2N1M0 (tumors o5 cm with 1-3 involved axillary nodes), and stage III is T1-2N2-3M0 (tumors o5 cm with four or more axillary nodes) or T3N1-3M0 (tumors over 5 cm with involved axillary nodes) or T4N0-3M0 (adherent to skin or chest wall, or inflammatory breast cancer). Within the new system, N1 ¼ 1-3 nodes, N2 ¼ 4-9 nodes, and N3 ¼ 10 involved nodes. Under this system all of the patients in the HRQL study are re-categorized as having stage III breast cancer.
Treatment regimen
Patients received four cycles (repeated every 21 days) of conventional fluorouracil, adriamycin, and cyclophosphamide (FAC) chemotherapy. The four cycles of FAC chemotherapy were administered as follows: 5-fluorouracil 500 mg/m 2 all cycles, doxorubicin 50 mg/m 2 all cycles, and cyclophosphamide 500 mg/m 2 cycles 1 and 2, then 2000 mg/ m 2 cycles 3 and 4. FAC cycles 3 and 4 were supported with G-CSF 300 mg (o70 kg) or 480 mg SC (470 kg) from day 7 until ANC recovery 41.5 Â 10 9 /l. FAC was followed in 4-6 weeks by one course of HDC supported by ASCT.
The 
Points of assessment
HRQL was measured seven times over a 2-year period: at baseline when the patient attended the clinic prior to beginning treatment (T1), day 1 of the third cycle of FAC (T2), 3 weeks after administration of HDC (T3), 6 months after study enrollment or approximately 8 weeks post-HDC (T4), and 12, 18, and 24 months post-enrollment (T5, T6, and T7, respectively). The seven time points were based on clinical judgement and were designed to capture the most probable periods of change in HRQL over the treatment trajectory and also to minimize patient burden. All of the questionnaires were designed for patient self-report and were completed in the clinic where possible. Clinical trial nurses were given a brief in-service training on the questionnaires and they were available to answer any questions, particularly on the first administration. Of 364 questionnaires, 149 were mailed to patients who did not come to the clinic as scheduled.
Instruments
HRQL is defined as a multidimensional construct that assesses three broad areas of health: physical, psychological, and social. 12, 13 The Functional Living Index-Cancer (FLIC) is a cancer-specific HRQL measure with demonstrated reliability and validity. 12 It assesses the effect of the symptoms of cancer and its treatment on one's functional ability in all areas of life. It consists of 22 items with sevenpoint Likert/visual analogue scales (VAS) with written anchors at each end. The VAS was used for this study. The FLIC results in a single total score (the mean of all the items) and five subscale scores: physical wellbeing, psychological wellbeing, hardship due to cancer, social wellbeing, and nausea. Scores range from 0 to 150, with higher scores representing a better HRQL.
The EQ-5D is a preference-based generic HRQL measure designed to be used alongside condition-specific tools to assess more general aspects of health outcomes.
14 It has been used in clinical trials and in economic analyses in cancer patients. 9, 10, 15 It requires respondents to rate their level of problem (no problem, moderate problem, inability/ severe problem) on each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression. Health states are converted to an EQ-5D index (range À0.59 to 1) using standardized weights derived from time trade-off measurements. 16 Preference-based indices are anchored on perfect health (1) and death (0). To assess perception of health changes, patients were asked 'Compared with my general level of health over the past 12 months, my health state today is: better, much the same, or worse'.
Specific aspects of quality of life and symptoms in the past 2 weeks were each measured with a 0-140 mm VAS, with higher scores representing better health. These VAS scales were designed specifically for cancer patients. 4 VAS scales have been shown to have good reliability and validity for assessing global QOL in cancer patients. 17 Patient perception of overall quality of life (QOL VAS) was measured by the question: 'Overall, how would you rate your quality of life over the past 2 weeks?' (anchored at very negatively and very positively). Specific aspects of quality of life included upsetting thoughts about one's appearance, worry about the future, and the effect of their physical condition on the quality of sexual interest.
Symptoms assessed with the VAS included difficulty sleeping, headaches, abdominal pain, nausea and vomiting, appetite, tiredness due to treatment, fever, shortness of breath, and cough. 4 At each time period, patients were asked to note any side-effects experienced as a result of other treatments such as radiotherapy.
Statistical analysis
Frequencies and measures of central tendency (mean) and dispersion (standard deviation) were used to describe patient demographics and HRQL at the seven time periods.
Pearson correlation coefficients, t-tests for independent means, and analysis of variance (ANOVA) were used to test the effect of age, marital status, years of education, stage of cancer, menopausal status, and timing of surgery (pre-or post-HDC) on HRQL at baseline. t-Tests and w 2 tests were used to assess differences in patients with and without missing questionnaires. A Friedman test for nonparametric data was used to test changes in each EQ-5D dimension over time. A one-way repeated-measures analysis ANOVA was used to assess differences in HRQL over time. 18 Under the null hypothesis, one would expect random variation of each person's responses over different measurement periods. This variation is taken into account by the repeated-measures model and is used to reduce the mean square error term in the F-test. Thus, greater power is possible in the repeated-measures design. The F-test reflects the differences among the different measurement occasions. If the F-test was significant, post hoc contrasts were conducted to test for pairwise mean differences and a Bonferroni correction was used to control for type 1 error.
Results
A total of 52 patients ranging in age from 21 to 62 years (mean age 44.7, s.d. 8.5) were enrolled in the study. Patient demographics and baseline characteristics are shown in Table 1 . Of the 52 patients, 37 were pre-menopausal and 34 received HDC post-operatively. In all, 22 patients had a modified radical mastectomy, 19 had a total mastectomy, and 11 had a segmental resection. All patients received uniform treatment, including ASCT, and had supportive hospitalizations. The median number of axillary lymph nodes involved for the post-op group was 10 (4-29), 28 patients were estrogen receptor positive, 15 relapsed at a median of 13 months (1-49), with five patients relapsing more than 24 months post-surgery. Five patients received tamoxifen just after finishing radiotherapy. Table 2 shows the response rate for HRQL forms at each time period. Of the 52 patients in the study, four did not complete baseline HRQL forms; three of these four completed four to six of the subsequent HRQL forms. Four patients did not complete the second HRQL during FAC (T2); three of these completed all five of the subsequent forms. At 2 years, 37 patients completed HRQL questionnaires; eight patients had died, two had moved out of the province, two lived outside the city, and one had relapsed. Of the eight patients who died, all but one patient died of relapsed breast cancer. The exception died of secondary acute leukemia. Of these, five patients had completed a HRQL questionnaire in the administration just prior to their death and two patients missed one questionnaire in the assessment period just prior to their death. In all, 27 patients completed HRQL questionnaires at all seven time periods. There was no significant difference in age, years of education, marital status, stage of cancer, menopausal status, timing of surgery, or type of surgery between patients with all seven questionnaires and those with missing questionnaires. There were no significant mean differences in HRQL, HRQL subscale scores, or specific aspects of quality of life and symptoms at any time period between those with and without missing HRQL questionnaires. All patients with data at each time period were used for all analyses, with the exception of the repeated-measures ANOVA. In an earlier paper that followed patients up to 2 months post-HDC, we found the EQ-5D to be responsive to the changes associated with HDC.
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Health-related quality of life
There was no significant difference in age, marital status, years of education, stage of cancer, menopausal status, or timing of surgery (pre or post-HDC) on the three HRQL measures at baseline. Using repeated-measures ANOVAs, all three HRQL measures showed a significant difference over measurement occasions (Table 3 ). There was a significant decrease in HRQL from T1 to T3 and a return to baseline levels by T4 (8 weeks post HDC). From T4 to T7 (2 years post-enrollment), the FLIC showed a significant improvement (mean change 20.68). While the EQ-5D and QOL VAS tended to improve from T4 to T7, the difference was not significant. When asked of their perception of health changes, at T5, compared with their general level of health over the past 12 months, 35 of 39 patients reported their health state as better, three as much the same, and one as worse. At T7, 25 of 37 patients reported their health state as better, 10 as much the same, and two as worse than 1 year ago. Repeated-measures ANOVAs of the FLIC subscales showed a significant difference over measurement occasions (Figure 1 ). There was a significant worsening in physical wellbeing from T1 to T3 (mean change 29.39), a return to baseline by T4, and a significant improvement from T4 to T7 (mean change 24.13). Psychological wellbeing improved significantly from T1 to T5 (mean change 19.66) and then remained stable to T7. Hardship due to cancer was the lowest of the subscales at T1 (m ¼ 72.30), did not change at T3, and improved significantly from T3 to T4 (mean change 37.52) and from T4 to T7 (mean change 20.06). Social wellbeing and nausea decreased significantly from T1 to T3, returned to baseline levels by T4, and remained stable through T7. Table 4 shows the distribution of responses for each EQ-5D dimension at each time period. The distribution was similar for the group of 27 cases with complete data across all time periods (results not shown). The Friedman test showed significant changes over time for EQ-5D mobility (P ¼ o0.0001), self-care (P ¼ 0.006), usual activities (P ¼ o0.0001), and anxiety/depression (P ¼ 0.001), and no significant change over time for pain/discomfort. At baseline, 13 out of 48 patients reported no problems on any of the EQ-5D dimensions. The least problems reported across all time periods were for mobility and self-care. At 8 weeks post-HDC (T4), 57% of patients had some problems or were unable to perform their usual activities, 53% reported some pain or discomfort, and 49% had moderate or extreme anxiety/depression. By 2 years post-enrollment, 24% of patients had some problems with their usual activities compared to 38% with some problems and 2% with severe problems at baseline. The highest percentage of problems at 2 years was 38% for pain or discomfort, compared to 44% at baseline. In all, 30% of patients reported some problems and 3% reported extreme problems with anxiety or depression at 2 years.
Specific aspects of HRQL and symptoms
Using a repeated-measures ANOVA, the VAS measures of sexual interest (F(6,102) ¼ 4.42, P ¼ 0.001), worry about the future (F(6,102) ¼ 9.96, P ¼ o0.0001), and appearance (F(6,102) ¼ 9.20, P ¼ o0.0001) all showed a significant difference over measurement occasion, but their patterns of change differed. Figure 2 shows the mean changes over time for the three VAS measures compared to the overall QOL VAS. The quality of sexual interest decreased significantly from T1 to T3 (mean change 39.58), returned to baseline levels by T4, and remained stable through T7.
Although mean sexual interest scores followed a pattern similar to quality of life scores over time, they were consistently lower and also more variable than quality of life scores, using the full range of the scale at each time T7  T6  T5  T4  T3  T2  T1   140  120  100 
Table 4
Percentage of responses for levels of EQ-5D at each assessment period Level  T1  T2  T3  T4  T5  T6  T7 period. To assess if patient characteristics determined the quality of sexual interest, the mean sexual interest score across all time periods was regressed on age, marital status, menopausal status, tamoxifen, and type of surgery (lumpectomy vs mastectomy). Menopausal status, type of surgery, and tamoxifen had no significant effect on the quality of sexual interest. With age and marital status in the regression equation, younger women and those who were either married or living with a partner were significantly more likely to have problems with sexual interest (adjusted R 2 41%).
EQ-5D
Worry about the future was worse at T1 (mean ¼ 56.81), improved significantly at T2 (mean 81. 19) , and improved significantly from T2 to T7 (mean change 24.15). Upsetting thoughts about one's appearance improved significantly over time from T1 to T7 (mean change ¼ 33.33).
In addition to decreased sexual interest, difficulty sleeping and headaches were the most common problems from 1 to 2 years post enrollment. Table 5 shows the percentage of patients who scored in the negative half of the VAS symptom scales (scores o70). For most symptoms the highest percentage of problems was at T3. At T7, 16-19%   T7  T6  T5  T4  T3  T2  T1   140  120  100  80  60  40   140  120  100  80  60  40   140  120  100  80  60  40   140  120  100  80  60 
Table 5
Percentage of cases reporting in the negative half of the symptom VAS T1  T2  T3  T4  T5  T6 of patients also had problems with shortness of breath, cough, upsetting thoughts about their appearance, and worry about the future. At each time period, patients were asked to report any specific side-effects from treatment, other than chemotherapy. At T4 (8 weeks post-HDC), 82% of respondents (37 of 45) reported side-effects, most often from radiotherapy. In all, 22 patients reported skin problems such as burning, redness, and itchiness, 17 reported fatigue, three reported muscle or bone pain or nausea, and one reported lung damage with a cough. At T5 (1 year post-study entry), 25 of 40 patients reported side-effects. These included fatigue (n ¼ 9), skin problems (n ¼ 9), muscle aches or pain (n ¼ 6), night sweats due to tamoxifen (n ¼ 1), and radiation scarring on the lung (n ¼ 1). At T6 and T7, 16 and 18 patients, respectively, reported side-effects. These were also primarily attributed to radiotherapy.
Symptom or QOL
T7 (n ¼ 48) (n ¼ 48) (n ¼ 48) (n ¼ 45) (n ¼ 40) (n ¼ 36) (n ¼ 37)
Discussion
In this paper, both the short-term and long-term effects of HDC with ASCT on HRQL in women with breast cancer and poor prognosis are reported. Most other studies in the autologous bone marrow transplant (ABMT) and ASCT literatures have been cross-sectional 6, 7 or have followed patients only up to 1 year. 4, 8 Many studies have also used heterogenous groupings of cancer patients. 20, 21 All of the patients in this study had stage III breast cancer under the new classification system. They all also received the same chemotherapy. They lived long enough and well enough for data to be collected for 2-year follow-up. With data also obtained sequentially at important points before, during, and immediately following active treatment, a very detailed picture of the HRQL of poor prognosis breast cancer patients is provided. This picture includes problems encountered as well as considerable positive information about the HRQL of patients whose future is threatened by poor prognosis.
All three measures of HRQL used in this study showed a similar pattern of change, decreasing following the administration of HDC, and returning to baseline levels at 8 weeks post-HDC (T4). In the short term, HRQL was impacted negatively by treatment but quickly rebounded. This finding has been recorded in other studies. 22 FLIC scores at 2 years (T7) in our study were similar to those in a crosssectional study of breast cancer patients who had undergone HDC-ABMT support at least 1 year prior to the study. 6 In patients with refractory or relapsed nonHodgkin's lymphoma or Hodgkin's disease, the EQ-5D index scores before ABMT were the same as our findings, but lower at 14 days post-transplantation than the T3 assessment in our study. 23 Differences could be due to timing of assessment in addition to actual differences in HRQL between patients with different cancers.
At 2 years post-study entry, cancer-specific HRQL was better than baseline and the majority of respondents felt that their health had improved in the past year. MacquartMoulin et al 8 also found that that emotional functioning and global QOL were higher than baseline levels in patients with inflammatory breast cancer 1 year following treatment with HDC. In a longitudinal study of disease-free survivors of breast cancer, Ganz et al 24 found an improvement in emotional wellbeing from 1 to 5 years following diagnosis to 5 years later.
Although psychological health continued to improve following treatment, approximately one-third of the patients reported problems with anxiety or depression 1 and 2 years following the beginning of treatment. This percentage is compatible with findings from other studies dealing with emotional distress in cancer patients. 25 Other studies of psychological wellbeing of cancer patients following HDC with ASCT or ABMT have reported anxiety and depressive symptoms in the long-term followup of patients. [26] [27] [28] [29] Our results showed that, despite overall high HRQL scores following treatment, patients reported problems with sexual interest, sleeping, headache, shortness of breath, cough, and pain or discomfort up to 2 years post-study entry. All of the patients in this study received radiation treatment and had many associated and persistent sideeffects. The radiation treatment itself therefore impacted HRQL substantially. Surgeries the women received were scheduled at different times in the treatment process, thus not allowing for direct comparisons at one point in time. Consequently, the previously well-documented impact of differing surgical treatments on psychological and psychosexual functioning of breast cancer patients 30, 31 could not be distinguished.
Difficulties with sexual interest and sexual functioning have been reported in breast cancer patients 4, 6, 26 and other cancer patients undergoing HDC and bone marrow or stem cell transplantation. 28, 32 In our study, which did not measure sexual functioning, decreased sexual interest was a problem for about one-third of the patients 1-2 years following HDC and ASCT, and was related to age and marital status. This may be due in part to the effects of chemotherapy causing premature ovarian failure in the younger patients. 33 Low sexual interest can understandably cause more potential life disruption for those who are married or in other long-term relationships.
Pain or discomfort was reported by approximately onethird to one-half of patients from 1 to 2 years postenrollment. All of the symptoms except fever were reported by over 10% of patients from T5 to T7 and may account for the pain or discomfort responses. Winer et al reported mild to moderate pain in 43% and severe pain in 5% of patients at least 12 months following HDC with ABMT. 6 Coughing was reported as a problem by about 19% of patients at T7. It could be due to a degree of radiation fibrosis of the lungs, possibly accompanied by de-conditioning, fatigue, or even mild impairment of cardiac function. Consequently, despite overall good HRQL after the immediate treatment phase, physical problems persisted for some patients. For those patients with increasing physical problems, such as cough, at 2 years, disease progression may be heralded.
Fatigue was not a long-term problem for the majority of women in our study. However, they reported difficulties with sleeping up to 2 years post-enrollment. Insomnia and fatigue have been reported in breast cancer patients following HDC and ABMT. 6 Although studies have shown that post-treatment fatigue is unrelated to type of surgery, type of adjuvant therapy, or time since diagnosis, it has been related to sleep disturbance, psychological wellbeing, functional impairment, physical activity, and social support. 1 Difficulty sleeping could be a result of an increased frequency of night-time vasomotor symptoms secondary to chemotherapy-induced ovarian failure 1 in the patients in our study, the majority of whom were pre-menopausal prior to HDC with ASCT. Sleep problems may also be related to post-treatment pain and chemotherapy sideeffects.
A limitation of our study may be the generalizability of findings. Clinically, the women in the study had diagnoses that fit the classification of the new stage III and therefore should be comparable to other patients outside of Western Canada in terms of disease factors. The women in the study are not representative of the entire breast cancer population whose mean age is usually in the mid-to-late 50s or even in the 60s 34 but are comparable to those receiving HDC with ASCT. In particular, they are typically younger. 34 The descriptions of such factors as age and menopausal status that are forthcoming from the study are similar to those found in other HDC studies. 22, 35 The problems of missing data as a limitation in cancer trials in which data may be more available from patients with a better HRQL are well documented. 36 Although there were missing data at each time period in this study, the return rate of questionnaires was 80-92% across the seven assessment periods. Five of the eight patients who died completed a HRQL questionnaire in the assessment period immediately prior to their death. We found no significant differences in baseline patient characteristics or HRQL at any time period between those with and without missing data.
Some factors that were not measured in the study, such as social support, socioeconomic status, and stressful life events, are important moderating variables in the interpretation of HRQL changes over time. Cultural and psychosocial differences have a role to play in HRQL and this omission can also be viewed as a limitation. It is not known whether patients who completed the questionnaires in the clinic or at home differed in their responses. These are further limitations of the study.
The treatment the patients in this study received is still considered to be controversial and experimental. 37 However, there is continued interest in pursuing clinical trials with the treatment. 35 The present study provides comprehensive, prospective, short-, and long-term information. Therefore, the findings from this study will have application in the design of future research studies. In addition, to our knowledge, this is the first study that has used the EQ-5D index in a longitudinal study of breast cancer patients. Our findings provide evidence of the characteristics of the EQ-5D that can be used in the planning of economic analyses of breast cancer treatments.
In summary, all three measures used in the study showed a similar pattern of change with HRQL decreasing following the administration of HDC, and returning to baseline levels post-HDC. Although overall cancer-specific HRQL was significantly better at 2 years than at baseline, many patients also continued to report problems with sexual interest, sleeping, pain or discomfort, and psychological wellbeing. Information and counseling on how treatment may affect one's sexual life, especially with younger patients, may help patients to cope with sexual difficulties. Psychological interventions employed in a timely fashion may improve HRQL not only in the short term, during active treatment, but also in the long term.
